Please assess the completion status of the following clinical trial:

Trial Title: High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and a positive culture or diagnosed by polymerase chain reaction (PCR) methods or by intradermal skin testing (Montenegro test).~* Number of lesions: 1 to 3 ulcerative lesions.~* Lesion´s diameter: 1 to 5 cm.~* Disease duration: up to three months.~Exclusion Criteria:~* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)~* Immunodeficiency or antibody to HIV~* Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, HIV, or other major infectious diseases~* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months~  * Lack of suitability for the trial:~* Negative parasitology (aspirate/biopsy/PCR)or negative Montenegro test~* Any history of prior anti-leishmania therapy~* Any condition which compromises ability to comply with the study procedures~  * Administrative reasons:~* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative)~* Anticipated non-availability for study visits/procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fluconazole (Type: EXPERIMENTAL): Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
- Meglumine Antimoniate (Type: ACTIVE_COMPARATOR): Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).